However, to date, comprehensive genetic and transcriptomic characterization of AITL is established from limited cases not exceeding 25 AITL [23, 24, 25, 26]; herein, we assembled a large AITL cohort through a consortium of hospitals in Asia, Europe, and North America, and performed whole‐exome sequencing (WES), transcriptional and methylation profiles and generated AITL patient‐derived xenografts (PDX) and elucidated novel targetable mechanisms using engineered CD4+ T‐cells. This evidence concerns the gene CD4 and angioimmunoblastic T-cell lymphoma.